- Home
- LXEH vs OVID Comparison
LXEH vs OVID Comparison
Compare LXEH & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- OVID
- Stock Information
- Founded
- LXEH 2001
- OVID 2014
- Country
- LXEH China
- OVID United States
- Employees
- LXEH N/A
- OVID N/A
- Industry
- LXEH Other Consumer Services
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- OVID Health Care
- Exchange
- LXEH Nasdaq
- OVID Nasdaq
- Market Cap
- LXEH 25.1M
- OVID 20.6M
- IPO Year
- LXEH 2020
- OVID 2017
- Fundamental
- Price
- LXEH N/A
- OVID $0.34
- Analyst Decision
- LXEH
- OVID Strong Buy
- Analyst Count
- LXEH 0
- OVID 4
- Target Price
- LXEH N/A
- OVID $3.13
- AVG Volume (30 Days)
- LXEH 303.4K
- OVID 1.6M
- Earning Date
- LXEH 04-30-2025
- OVID 08-12-2025
- Dividend Yield
- LXEH N/A
- OVID N/A
- EPS Growth
- LXEH N/A
- OVID N/A
- EPS
- LXEH N/A
- OVID N/A
- Revenue
- LXEH $4,493,795.00
- OVID $548,000.00
- Revenue This Year
- LXEH N/A
- OVID N/A
- Revenue Next Year
- LXEH N/A
- OVID $5.32
- P/E Ratio
- LXEH N/A
- OVID N/A
- Revenue Growth
- LXEH N/A
- OVID 15.61
- 52 Week Low
- LXEH $1.20
- OVID $0.24
- 52 Week High
- LXEH $50.08
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- LXEH 29.05
- OVID 56.68
- Support Level
- LXEH $1.49
- OVID $0.30
- Resistance Level
- LXEH $1.85
- OVID $0.33
- Average True Range (ATR)
- LXEH 0.17
- OVID 0.03
- MACD
- LXEH 0.08
- OVID 0.00
- Stochastic Oscillator
- LXEH 3.19
- OVID 84.62
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.